CIRIUM
21.10.2021 04:02:10 CEST | Business Wire | Press release
Chinese travelers are leading the airline travel recovery, with 96% intending to travel, according to a new survey by Cirium, the aviation analytics company. 81% of respondents say they plan to fly at least once within the next 12 months and 50% plan to fly by this autumn. Of those planning to travel, 73% stated it was for leisure with only 24% planning business travel.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211020005941/en/
The pent-up demand is also reflected in China’s passenger traffic, which is showing signs of a strong recovery. As of September 2021, China traffic was at 87% of 2019 levels — way ahead the rest of Asia (42%).
The survey revealed that two thirds (66%) of Chinese travelers have taken a domestic flight since the start of the pandemic. Cirium schedules data reveal domestic travel in Q4 is primed to outpace pre-pandemic levels, growing by some 15% compared to Q4 2019.
Following months of restrictions aligned to China’s Zero-COVID policy, pent-up demand for a major return to international and regional travel is palpable.
More than half (61%) of respondents shared that they are ready to travel out of mainland China once borders are open, with Southeast Asia as the region of choice, followed by Europe, Australia/New Zealand and East Asia.
Jeremy Bowen, CEO at Cirium said: “The Cirium survey highlights the Chinese traveler’s confidence in flying domestically and pent-up demand when it comes to flying internationally. There is a clear preference for Southeast Asia, so the challenge faced is to bring back travel to other markets such as East Asia, which was a previous top destination.”
“The results also show the importance of health and safety measures, which will need to be in place to increase the confidence in traveling internationally from China.”
While Chinese travelers show confidence in flying again, 35% of those surveyed claimed that they would be less likely to travel by air, post-pandemic. They were principally concerned over health, hygiene and safety.
Almost all of the respondents (96%) support the mandatory requirement to wear a face mask when travelling by air. And over 85% support the introduction of health passports as a prerequisite to flying, and the use of apps that promote touchless travel.
When choosing an airline, respondents placed importance on mandatory mask wearing (66%), improved cleaning processes in place (65%) and proof of negative pre-departure COVID-19 test (62%).
Chinese travelers were divided when it came to the time spent at the airport. 53% of travelers claimed they will reduce the amount of time they spend at airports, compared to 21% who will look to increase their time at the airport as they feel safer with the COVID-19 safety measures in place.
The survey was carried out by independent market intelligence firm AudienceNet on behalf of Cirium. The firm interviewed over 2,060 adults in mainland China between August 30 and September 8, 2021. The margin of error in the reported data did not exceed +/-3% at the 95% confidence level.
Click here to read the full China Cirium Traveler Intelligence Report .
Additional insights on air travel in the full report include:
- The importance of flying on modern aircraft
- Future use of airport lounges
- Cabin class preferences
- Top destinations outside of mainland China
Ends
For further information please follow Cirium updates on WeChat or visit www.cirium.com .
About Cirium
Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX , a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211020005941/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFCO Demonstrates Sustainability Leadership by Combining Record Environmental Performance With Business Growth29.10.2026 13:38:00 CET | Press release
IFCO’s ESG Report 2026 highlights 833k metric tons of carbon emissions avoided in customer supply chains and a record 2.6 billion reusable packaging trips. IFCO, a global leader in reusable packaging solutions for fresh food, today published its ESG Report 2026. The report covers July 1, 2025, to June 30, 2026 and marks the first year of reporting against IFCO's Thriving with Purpose 2030 ESG strategy. During fiscal year 2026, the company managed an impressive 2.6 billion reusable packaging container (RPC) trips while reducing material greenhouse gas emissions by 11%. At the same time, customers using IFCO RPCs avoided 832,970 metric tons of CO₂e emissions, an increase of 13% compared with the previous year. Michael Pooley, CEO of IFCO: "The first year of our Thriving with Purpose 2030 ESG strategy showed that growth and sustainability go hand in hand. By expanding our network, investing in IFCO Digital, and scaling our circular model for reusable transport packaging, we are building a
Parse Biosciences and Nomic Announce 100 Million Cell, Multimodal AI-ready Dataset for Immune Biology29.10.2026 13:00:00 CET | Press release
Licensable perturbation dataset to include transcriptomes and proteomic secretomes for understanding the human immune response Parse Biosciences, the leading provider of scalable and accessible single-cell sequencing and a QIAGEN company, and Nomic Bio, a leader in high throughput proteomic profiling, today announced their partnership to generate Cascade, a 100 Million cell foundational dataset to understand the human immune response. The dataset's scale and depth will give pharma partners cellular- and protein-level insight into immune biology, accelerating their ability to identify and validate new drug targets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261029559438/en/ Cascade has already drawn foundational partner commitments from leading pharmaceutical and biotechnology companies, including GSK, Pfizer, Sanofi, Graph Therapeutics, and Turbine, underscoring the demand for large-scale, multimodal immune data in drug
CSC Named Winner of the Top InfoSec Innovator Award for Most Innovative DNS Security29.10.2026 13:00:00 CET | Press release
CSC’s Subdomain Monitoring recognized for innovation in mitigating subdomain hijacking risks from dangling DNS CSC, an enterprise-class domain registrar and world leader in mitigating brand, fraud, domain, and Domain Name System (DNS) threats, today announced that its Subdomain Monitoring solution took top honors for Most Innovative DNS Security in Cyber Defense Magazine’s 2026 Top InfoSec Innovator Awards. CSC introduced Subdomain Monitoring after analyzing close to half a million DNS records and finding that many companies were exposed to subdomain takeovers due to dangling DNS. CSC’s solution helps enterprises reduce this risk and secure their online ecosystems. It was the first and only technology on the market to ease the burden of tracking and maintaining DNS records and purging unused zone records to prevent subdomain hijacking. Subdomain Monitoring, powered by CSC’s one-of-a-kind DomainSecSM threat intelligence platform, alerts DNS administrators and security engineers when it
Two Single-Pill Triple Combination Lipid-Lowering Therapy Applications Validated in The European Union29.10.2026 12:27:00 CET | Press release
EMA has validated two marketing authorization applications from Daiichi Sankyo in the EU for single-pill triple-combinations of established lipid-lowering agents: bempedoic acid, ezetimibe, and either atorvastatin or rosuvastatin If approved, the proposed therapies could be the first oral single-pill triple-combinations for lipid-lowering in the EU, aiming to simplify treatment for patients requiring multiple lipid-lowering agents The submissions reflect the commitment of Daiichi Sankyo to addressing unmet needs in cardiovascular disease The European Medicines Agency (EMA) has validated two marketing authorization applications (MAA) from Daiichi Sankyo (TSE: 4568) for oral, single-pill triple-combination therapies. The applications seek approval for the treatment of adults with primary hypercholesterolemia or mixed dyslipidemia to reduce low-density lipoprotein cholesterol (LDL-C) levels and cardiovascular (CV) risk. Despite the availability of effective therapies, treatment discontinu
NIQ and Google Partner to Advance Agentic Commerce29.10.2026 11:45:00 CET | Press release
Built with Google Cloud and Gemini for business, NIQ and Google commit to transforming AI-driven product discovery, availability, and measurement Today, NielsenIQ (NYSE: NIQ) and Google announced a broad collaboration to advance agentic commerce, aiming to bring NIQ’s global retail and product intelligence together with Google’s AI commerce ecosystem to improve product discovery and local availability. NIQ and Google are looking to complement Google's extensive Shopping Graph of more than 60 billion product listings with NIQ’s Commerce Intelligence. NIQ is also naming Google Cloud as a primary AI and cloud services provider, and plans to deploy Gemini for business across its global workforce. As AI evolves from helping consumers discover products to recommending and purchasing them, brands and retailers increasingly rely on trusted product information, real-world availability, and measurement. The partnership is designed to help make agentic commerce even more reliable and measurable,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom